Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
RLYB Rallybio
13.600
+0.340+2.56%
Post Mkt Price
13.60000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
30.73% 147.37M 26.36% 161.41M 25.03% 175.33M 25.03% 175.33M
-Cash and cash equivalents
-46.11% 60.75M -36.26% 81.43M 25.03% 175.33M 25.03% 175.33M
-Short-term investments
-- 86.62M -- 79.98M -- -- -- --
Prepaid assets
21.55% 6.93M 559.05% 6.37M 438.42% 5.54M -- --
Total current assets
30.29% 154.3M 30.36% 167.78M 28.04% 180.87M -- --
Non current assets
Net PPE
253.27% 1.08M 270.51% 1.16M 78.05% 511K -- --
-Gross PPE
253.27% 1.08M 270.51% 1.16M 86.72% 717K -- --
-Accumulated depreciation
-- -- -- -- -112.37% -206K -- --
Investments and advances
-83.31% 227K 26.52% 415K 159.68% 805K -- --
Total non current assets
-21.49% 1.31M 145.47% 1.57M 120.44% 1.32M -- --
Total assets
29.57% 155.61M 30.93% 169.35M 28.43% 182.19M 28.43% 182.19M
Liabilities
Current liabilities
Payables
-75.86% 633K -64.87% 1.06M -61.81% 603K -- --
-accounts payable
-75.86% 633K -64.87% 1.06M -61.81% 603K -- --
Current accrued expenses
35.71% 6.5M 49.67% 4.6M 39.49% 5.95M -- --
Current debt and capital lease obligation
-- 150K -- 148K -- -- -- --
-Current capital lease obligation
-- 150K -- 148K -- -- -- --
Current liabilities
-1.75% 7.28M -4.59% 5.8M 12.12% 6.55M -- --
Non current liabilities
Long term debt and capital lease obligation
-- 478K -- 517K -- -- -- --
-Long term capital lease obligation
-- 478K -- 517K -- -- -- --
Non current accrued expenses
-- 0 -- 0 166.67% 32K -- --
Total non current liabilities
-99.74% 478K -99.72% 517K -99.98% 32K -- --
Total liabilities
-95.91% 7.76M -96.64% 6.32M -96.5% 6.58M -96.5% 6.58M
Shareholders'equity
Share capital
-- 3K -- 3K -- 3K -- --
-common stock
-- 3K -- 3K -- 3K -- --
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
-76.58% -126.11M -80.01% -108.53M -100% -94.03M -- --
Paid-in capital
-- 274.33M -- 271.68M -- 269.63M -- --
Gains losses not affecting retained earnings
-- -371K -- -122K -- -- -- --
Total stockholders'equity
-- 147.85M -- 163.04M -- 175.6M -- 175.6M
Total equity
313.15% 147.85M 377.38% 163.04M 481.54% 175.6M 481.54% 175.6M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
CEO: MacKay Ph.D., Martin W.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top